83 related articles for article (PubMed ID: 19942593)
1. Lipoatrophy of the footpad in HIV-treated patients is associated with increased PAI-1.
Eriksson LE; Nilsson Schönnesson L; Bratt GA
Biol Res Nurs; 2011 Jan; 13(1):89-96. PubMed ID: 19942593
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
[TBL] [Abstract][Full Text] [Related]
3. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
[TBL] [Abstract][Full Text] [Related]
5. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
Hammond E; McKinnon E; Nolan D
Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
[TBL] [Abstract][Full Text] [Related]
7. [Lipodystrophy in a patient treated with stavudine and didanosine].
Ruel M; Chemlal K; Melchior JC
Ann Med Interne (Paris); 1999 Apr; 150(3):269-71. PubMed ID: 10445099
[No Abstract] [Full Text] [Related]
8. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.
Boubaker K; Flepp M; Sudre P; Furrer H; Haensel A; Hirschel B; Boggian K; Chave JP; Bernasconi E; Egger M; Opravil M; Rickenbach M; Francioli P; Telenti A
Clin Infect Dis; 2001 Dec; 33(11):1931-7. PubMed ID: 11692306
[TBL] [Abstract][Full Text] [Related]
9. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy.
McComsey G; Maa JF
AIDS Read; 2003 Nov; 13(11):539-42, 559. PubMed ID: 14649623
[TBL] [Abstract][Full Text] [Related]
10. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Cournil A; Coudray M; Kouanfack C; Essomba CN; Tonfack CA; Biwolé-Sida M; Delaporte E; Bork K; Laurent C
Antivir Ther; 2010; 15(7):1039-43. PubMed ID: 21041920
[TBL] [Abstract][Full Text] [Related]
11. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
Yki-Järvinen H; Sutinen J; Silveira A; Korsheninnikova E; Fisher RM; Kannisto K; Ehrenborg E; Eriksson P; Hamsten A
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):688-94. PubMed ID: 12615670
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
[TBL] [Abstract][Full Text] [Related]
13. Changes in facial fat in HIV-related lipoatrophy, wasting, and weight gain measured by magnetic resonance imaging.
Paton NI; Yang Y; Tha NO; Sitoh YY
HIV Clin Trials; 2007; 8(4):227-34. PubMed ID: 17720663
[TBL] [Abstract][Full Text] [Related]
14. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents.
Dollfus C; Blanche S; Trocme N; Funck-Brentano I; Bonnet F; Levan P
HIV Med; 2009 May; 10(5):263-8. PubMed ID: 19178590
[TBL] [Abstract][Full Text] [Related]
15. Cervical lipomatosis in HIV-infected patients: a case-control study.
Palacios R; Galindo MJ; Arranz JA; Lozano F; Estrada V; Rivero A; Morales D; Asensi V; del Arco A; Muñoz A; Santos J
HIV Med; 2007 Jan; 8(1):17-21. PubMed ID: 17305927
[TBL] [Abstract][Full Text] [Related]
16. [Metabolic side effects of antiretroviral therapy].
van der Valk M; Reiss P
Ned Tijdschr Geneeskd; 2008 May; 152(22):1260-4. PubMed ID: 18590059
[TBL] [Abstract][Full Text] [Related]
17. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
van Griensven J; Zachariah R; Rasschaert F; Mugabo J; Atté EF; Reid T
Trans R Soc Trop Med Hyg; 2010 Feb; 104(2):148-53. PubMed ID: 19732926
[TBL] [Abstract][Full Text] [Related]
18. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive.
Bergersen BM; Sandvik L; Ellingsen I; Bruun JN
HIV Med; 2005 Jul; 6(4):260-7. PubMed ID: 16011531
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside analogues and mitochondrial toxicity.
Fleischer R; Boxwell D; Sherman KE
Clin Infect Dis; 2004 Apr; 38(8):e79-80. PubMed ID: 15095236
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
